Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q09028
UPID:
RBBP4_HUMAN
Alternative names:
Chromatin assembly factor 1 subunit C; Chromatin assembly factor I p48 subunit; Nucleosome-remodeling factor subunit RBAP48; Retinoblastoma-binding protein 4; Retinoblastoma-binding protein p48
Alternative UPACC:
Q09028; B2R6G9; B4DRH0; D3DPQ3; P31149; Q53H02; Q96BV9
Background:
Histone-binding protein RBBP4, also known as Chromatin assembly factor 1 subunit C, plays a pivotal role in chromatin assembly and remodeling. It is a core component of several key complexes, including CAF-1, HDAC, NuRD, PRC2, and NURF, which regulate chromatin metabolism, transcriptional repression, and development.
Therapeutic significance:
Understanding the role of Histone-binding protein RBBP4 could open doors to potential therapeutic strategies.